The SELECT trial (N=17,604) added a cardiovascular dimension: semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease, over a mean follow-up of 34.2 months [6]
This blog looks at the role of Somatropin Growth Hormone and related peptides in bone and joint health
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: systematic review and network meta-analysis
Regulatory status: No regulatory approval anywhere
Living with Thyroid Issues and GLP-1: Practical Tips If you and your healthcare professional decide that a GLP-1 is right for you, here are some practical ways to manage the journey: Prioritise Protein: As your appetite decreases, it is easy to eat too little protein
Food cannot diagnose anemia, thyroid changes, or other non-GLP-1 causes of hair loss